Clinical Study

Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients

Chonlaphat Sukasem^{1,2,3,4} , Chonlawat Chaichan,^{1,2} Thapanat Nakkrut,^{5,6} Patompong Satapornpong,^{1,2} Kanoot Jaruthamsophon,⁷ Thawinee Jantararoungtong,^{1,2} Napatrupron Koomdee,^{1,2} Suthida Sririttha,^{1,2,8} Sadeep Medhasi,⁹ Sarawut Oo-Puthinan,⁵ Ticha Rerkpattanapipat,^{4,10} Jettanong Klaewsongkram,^{4,11} Pawinee Rerknimitr,^{4,12} Papapit Tuchinda,^{4,13} Leena Chularojanamontri,^{4,13} Napatra Tovanabutra,^{4,14} Apichaya Puangpetch,^{1,2} and Wichai Aekplakorn¹⁵

¹Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

²Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand

³Ramathibodi Multidisciplinary Epilepsy Center, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

⁴The Thai Severe Cutaneous Adverse Drug Reaction (THAI-SCAR) Research Group, Bangkok, Thailand

⁵Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand

⁶Department of Pharmacy, Prasat Neurological Institute, Bangkok, Thailand

⁷Department of Pathology, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand

⁸Department of Clinical Pharmacy Practice, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand

⁹School of Medicine, Mae Fah Luang University, Chiang Rai, Thailand

¹⁰Division of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

¹¹Division of Allergy and Clinical Immunology, Skin and Allergy Research Unit, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

¹²Division of Dermatology, Skin and Allergy Research Unit, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

¹³Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

¹⁴Dermatological Division, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand

¹⁵Department of Community Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Correspondence should be addressed to Chonlaphat Sukasem; chonlaphat.suk@mahidol.ac.th

Received 17 August 2017; Revised 25 October 2017; Accepted 26 November 2017; Published 10 January 2018

Academic Editor: Riichiro Abe

Copyright © 2018 Chonlaphat Sukasem et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The *HLA-B**15:02 allele has been reported to have a strong association with carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) in Thai patients. The *HLA-B* alleles associated with carbamazepine-induced maculopapular exanthema (MPE) and the drug reaction with eosinophilia and systemic symptoms (DRESS) among the Thai population have never been reported. The aim of the present study was to carry out an analysis of the involvement of *HLA-B* alleles in carbamazepine-induced cutaneous adverse drug reactions (cADRs) in the Thai population. A case-control study was performed by genotyping the *HLA-B* alleles of Thai carbamazepine-induced hypersensitivity reaction patients (17 MPE, 16 SJS/TEN, and 5 DRESS) and 271 carbamazepine-tolerant controls. We also recruited 470 healthy Thai candidate subjects who had not

taken carbamazepine. *HLA-B*15:02* showed a significant association with carbamazepine-induced MPE ($P=0.0022$, odds ratio (OR) (95% confidence interval [CI]) = 7.27 (2.04–25.97)) and carbamazepine-induced SJS/TEN ($P=4.46 \times 10^{-13}$; OR (95% CI) = 70.91 (19.67–255.65)) when compared with carbamazepine-tolerant controls. Carbamazepine-induced SJS/TEN also showed an association with *HLA-B*15:21* allele ($P=0.013$; OR (95% CI) = 9.54 (1.61–56.57)) when compared with carbamazepine-tolerant controls. *HLA-B*58:01* allele was significantly related to carbamazepine-induced MPE ($P=0.007$; OR (95% CI) = 4.73 (1.53–14.66)) and DRESS ($P=0.0315$; OR (95% CI) = 7.55 (1.20–47.58)) when compared with carbamazepine-tolerant controls. These alleles may serve as markers to predict carbamazepine-induced cADRs in the Thai population.

1. Introduction

Hypersensitivity reactions such as maculopapular exanthema (MPE), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) are common with carbamazepine therapy [1]. MPE is characterized by a diffuse cutaneous erythema which can evolve into severe forms, presenting as vesicles and papules [2]. SJS and TEN, being severe and fatal hypersensitivity reactions, are characterized by epidermal necrosis and skin detachment [3]. The percentage of body surface involvement in SJS is <10%, SJS/TEN overlap is 10%–30%, and TEN is >30% [4]. DRESS includes serious maculopapular eruptions, fever, pharyngitis, eosinophilia, and systemic symptoms with an estimated mortality rate of up to 10% [5–7]. SJS and TEN are bullous reactions, whereas MPE and DRESS are nonbullous reactions [8].

Investigators have found strong phenotype- and ethnicity-specific associations between carbamazepine-induced hypersensitivity reactions and human leukocyte antigen (*HLA*) genes [9–11]. In 2004, Chung et al. reported a very strong association between carbamazepine-induced SJS and *HLA-B*15:02* allele in Han Chinese patients [12]. This study did not discuss *HLA* association with other cADRs associated with carbamazepine. The Food and Drug Administration (FDA) of the USA and the Clinical Pharmacogenetics Implementation Consortium (CPIC) have recommended screening for the *HLA-B*15:02* allele prior to initiating treatment with carbamazepine in patients with Asian ancestry [13, 14]. The association of the *HLA-B*15:02* allele with carbamazepine-induced SJS and TEN was reported in a systematic review and meta-analysis of the relationship between the *HLA-B*15:02* allele and carbamazepine-induced SJS and TEN among Han Chinese, Thai, and Malaysian populations [15]. Grover and Kukreti, in a meta-analysis study exploring the relationship between *HLA* alleles and carbamazepine-induced cutaneous adverse drug reactions (cADRs) among Asian patients treated with carbamazepine, showed an association of cases of carbamazepine-induced SJS and TEN with *HLA-B*15:02* and *HLA-B*15:11* alleles [16]. The authors also showed an association between cases of MPE, DRESS, and SJS/TEN caused by carbamazepine and the *HLA-A*31:01* allele. The *HLA-A*31:01* allele was reported to be associated with carbamazepine-induced hypersensitivity reactions among the subjects of European descent [17]. The *HLA-A*31:01* allele was significantly associated and was a distinct genetic predictor of carbamazepine-induced DRESS but not for carbamazepine-induced SJS/TEN in Chinese and Europeans [18]. Patients with carbamazepine-induced

MPE/DRESS showed an association with the *HLA-A*31:01* and *HLA-B*51:01* alleles in a study performed in Han Chinese patients [19].

The association between the occurrence of carbamazepine-induced cADRs and the *HLA* allele among the Thai population has been reported previously in only one study. In a case-control study in a Thai population, Tassaneeyakul et al. found a strong association between the presence of the *HLA-B*15:02* allele and SJS/TEN induced by carbamazepine [20]. More recently, a Thai patient with carbamazepine-induced SJS did not show the presence of the *HLA-B*15:02* allele but showed the presence of the *HLA-B*15:21* allele [21]. There is no published data of genetic association of carbamazepine-induced MPE and DRESS within the Thai population. In the present study, we sought to investigate the *HLA-B* allele-phenotype correlations in carbamazepine-induced MPE, DRESS, and SJS/TEN in Thai subjects.

2. Materials and Methods

2.1. Subjects and Characteristics. This study was carried out as a retrospective and prospective case-control study. From 2011 to 2016, patients with carbamazepine-induced cADRs were retrospectively and prospectively enrolled from the Faculty of Medicine Ramathibodi Hospital, Mahidol University, the Faculty of Medicine, Chulalongkorn University, Prasart Neurological Institute, and the Thai Severe Cutaneous Adverse Drug Reaction (THAI-SCAR) research group, Bangkok, Thailand. Among them, 38 patients with carbamazepine-induced cADRs were categorized into MPE (17 cases), SJS/TEN (16 cases), and DRESS (5 cases). Meanwhile, patients who had been taking carbamazepine for more than 6 months without evidence of cutaneous adverse effects were recruited as carbamazepine-tolerant controls ($n=271$). In addition, 470 healthy Thai subjects were recruited who were not taking carbamazepine. The study was approved by the Ethical Review Committee on Research Involving Human Subjects, Faculty of Medicine, Ramathibodi Hospital, Mahidol University.

2.2. Diagnosis of Carbamazepine-Induced Cutaneous Adverse Drug Reactions. Hypersensitivity reactions were classified according to the criteria of the RegiSCAR study, and a dermatologist and an allergist confirmed the diagnoses on the basis of the photographs, pathological slides, clinical morphology of the skin damage, and medical records [22].

MPE was defined as cutaneous fine pink macules and papules and lesions without mucosal or systemic symptoms [23]. SJS/TEN cases were defined according to the detached

body surface area as SJS (3–10%) and SJS/TEN overlap (10–30%) with or without associated systemic symptoms but not fulfilling the criteria of DRESS [22]. DRESS was defined as follows: presence of fever, maculopapular rash with internal organ involvement, and hematologic abnormalities [24].

2.3. DNA Isolation and HLA-B Typing. DNA extraction (MagNA Pure Compact nucleic acid purification kit, Roche Diagnostics Ltd., USA) was performed based on magnetic bead technology. DNA was aliquoted and stored at -20°C before HLA typing. HLA-B alleles were analyzed by the polymerase chain reaction-sequence-specific oligonucleotide probe (PCR-SSOP) assay and Luminex™ Multiplex Technology with well-established protocols [22]. In brief, PCR products were hybridized against a panel of oligonucleotide probes coated on polystyrene microspheres that have sequences complementary to stretches of polymorphic sequence within the target HLA-B alleles. The amplicon-probe complex was visualized using a colorimetric reaction and fluorescence detection technology. Data analysis for the HLA-B assays was performed with HLA fusion™2.0 software.

2.4. Statistical Analysis. Statistical analysis was performed with SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). Allele case-control comparisons were analyzed by Fisher's exact test. A two-sided P value < 0.05 was considered to be statistically significant.

3. Results

3.1. Subjects. Table 1 summarizes the clinical manifestations and demographic variables of the 38 cases and 271 carbamazepine-tolerant controls. Most cases received carbamazepine to treat epilepsy (29 cases), except for 9 patients who received carbamazepine to treat trigeminal neuralgia (5 cases), neuropathic pain (2 cases), bipolar disorder (1 case), and paroxysmal kinesigenic and nonkinesigenic dyskinesia (1 case). The mean treatment dose of carbamazepine in the carbamazepine-induced cADR patients was 325 ± 75 mg/day (mean $\pm$ standard deviation). There was no significant differences between the case and tolerant group in treatment dose of carbamazepine. The mean duration for the onset of cADR was 16 ± 7 days (mean $\pm$ standard deviation).

3.2. Association of HLA-B Alleles with Carbamazepine-Induced cADRs. Of the 38 patients who had carbamazepine-induced cADRs, 17 (44.74%) were found to carry the HLA-B * 15:02 allele. The HLA-B * 15:02 allele was observed in 4.06% (11/271) of carbamazepine-tolerant controls and 15.11% (71/470) of the general Thai population (Table 2). Our analysis of all subjects with cADRs and clinical control subjects showed a significant allelic association with HLA-B * 15:02 ($P = 7.35 \times 10^{-12}$), generating an odds ratio (OR) of 19.13 (95% confidence interval [CI], 7.94–46.09). A comparison of all 38 carbamazepine-induced cADR subjects with 470 general Thai subjects produced an OR of 4.55 (95% CI, 2.29–9.05, $P = 3.44 \times 10^{-6}$). Two patients with carbamazepine-induced cADRs carried HLA-B * 15:21, while the other HLA-B serotypes 75 were not detected in this study.

3.3. Association between HLA-B Alleles and Various Types of Carbamazepine-Induced cADRs. We analyzed the HLA-B association between 17 patients with carbamazepine-induced MPE and 271 carbamazepine-tolerant controls. We found two HLA-B alleles, HLA-B * 15:02 and HLA-B * 58:01, as significant in the carbamazepine-induced MPE (Table 3). The HLA-B * 15:02 allele was observed in 23.53% (4/17) of patients with carbamazepine-induced MPE, but only in 4.06% (11/271) of the carbamazepine-tolerant controls, giving a significant association with carbamazepine-induced MPE ($P = 0.002$; OR (95% CI) = 7.27 (2.04–25.97)). The HLA-B * 58:01 allele appeared in 29.41% (5/17) of patients with carbamazepine-induced MPE, which was more frequent than in carbamazepine-tolerant controls (8.12%, 22/271; $P = 0.007$; OR (95% CI) = 4.73 (1.53–14.66)). In the included general population, the carrier rates of HLA-B * 15:02 and HLA-B * 58:01 were 12.34% (58/470) and 12.13% (57/470), respectively. Comparing the difference of the HLA-B * 58:01 allele frequencies between the 17 patients with carbamazepine-induced MPE and 470 general subjects, HLA-B * 58:01 showed the significant association with carbamazepine-induced MPE ($P = 0.045$; OR (95% CI) = 3.02 (1.03–8.88)). As for the carbamazepine-induced SJS/TEN, the HLA-B * 15:02 and HLA-B * 15:21 alleles were most significantly detected (Table 4). 75% (12/16) of carbamazepine-induced SJS/TEN patients carried HLA-B * 15:02, which was more frequent than in carbamazepine-tolerant controls (4.1%, 11/271; $P = 4.46 \times 10^{-13}$; OR (95% CI) = 70.91 (19.67–255.65)). The HLA-B * 15:02 allele was present in 15.11% (71/470) of the general population and when we compared the difference of HLA-B * 15:02 frequency between carbamazepine-induced SJS/TEN patients and the general population, HLA-B * 15:02 showed a significant association with carbamazepine-induced SJS/TEN ($P = 6.9 \times 10^{-8}$; OR (95% CI) = 18.26 (5.79–57.61)). HLA-B * 15:21 was significantly associated with carbamazepine-induced SJS/TEN appearing in 12.5% (2/16) of cases as compared to 1.48% (4/271) and 0.43% (2/470) in carbamazepine-tolerant controls and general Thai subjects, respectively.

As shown in Table 5, the HLA-B * 58:01 allele was detected as significant in the carbamazepine-induced DRESS group when compared with the carbamazepine-tolerant control group ($P = 0.032$; OR (95% CI) = 7.55 (1.20–47.58)). The HLA-B * 58:01 allele was present in 40.00% (2/5) of the DRESS patients, but in only 8.12% (22/271) of the carbamazepine-tolerant controls and 12.13% (57/470) of the general population.

4. Discussion

HLA-B alleles are reported to be associated with hypersensitivity reactions during the clinical usage of carbamazepine [25]. Pharmacogenetic screening of HLA-B alleles before initiating carbamazepine therapy can prevent the risk of severe and life-threatening cutaneous adverse drug reactions. This study recruited patients with carbamazepine-induced hypersensitivity reactions, such as MPE, DRESS, and SJS/TEN and carbamazepine-tolerant patients from

TABLE 1: Clinical characteristic of patients with carbamazepine-induced cutaneous adverse drug reactions and carbamazepine-tolerant controls.

Demographic data	Cases (<i>n</i> = 38)	Tolerant controls (<i>n</i> = 271)	<i>P</i> value
Gender (<i>n</i> /%)			0.145
Male	24/63.15	137/50.6	
Female	14/33.84	134/49.4	
Age (mean/range)	44/24–64	32/10–54	0.010
Indication (<i>n</i> /%)			
Epilepsy	29/75.31	108/39.85	2.26×10^{-5}
Neuropathic pain	2/5.26	23/8.5	0.752
Trigeminal neuralgia	5/13.2	62/22.88	0.173
Bipolar disorder	1/2.6	10/3.7	1.000
Paroxysmal kinesigenic and nonkinesigenic dyskinesia	1/2.6	7/2.6	1.000
Autism	—	35/12.9	0.012
Schizophrenia	—	18/6.6	0.143
Others	—	8/3.0	0.602
Dose of carbamazepine; mg/day (mean $\pm$ SD)	325 $\pm$ 75	418 $\pm$ 19	0.397
Onset of cADRs; days (mean $\pm$ SD)	16 $\pm$ 7	—	—
cADRs (<i>n</i> /%)			
MPE	17/45	—	—
SJS/TEN	16/42	—	—
DRESS	5/13	—	—

cADRs: cutaneous adverse drug reactions; SJS/TEN: Stevens-Johnson syndrome/toxic epidermal necrolysis; DRESS: drug reaction with eosinophilia and systemic symptoms; MPE: maculopapular exanthema.

Thailand. We found the association between *HLA-B* alleles (*B**15:02 and *B**58:01) and carbamazepine-induced MPE. Further, the *HLA-B**15:02 and *HLA-B**15:21 alleles were strongly associated with carbamazepine-induced SJS/TEN, and carbamazepine-induced DRESS had significant association with *HLA-B**58:01 allele.

The evidence of association of different types of carbamazepine-induced cADRs was shown by Hung et al. in Han Chinese patients [3]. In their study, the *HLA-A**31:01 allele was associated with MPE ($P_c = 2.2 \times 10^{-3}$; OR (95% CI) = 17.5 (4.6–66.5)) and *HLA-B**15:02 was the susceptible allele for SJS/TEN ($P_c = 1.6 \times 10^{-41}$; OR (95% CI) = 1357 (193.4–8838.3)). Few studies have been conducted in the Thai population regarding the involvement of *HLA* alleles in carbamazepine-induced cADRs. The *HLA-A**31:01 allele has been mainly associated with carbamazepine-induced DRESS and MPE in Han Chinese population, Japanese, and European populations [17, 19, 26]. Our study did not perform *HLA-A* typing, and we might have missed the potential association between the *HLA-A**31:01 allele and carbamazepine-induced hypersensitivity reactions.

In 2008, Lochareernkul et al. first identified that the *HLA-B**15:02 allele was strongly associated with carbamazepine-induced SJS ($P = 0.0005$) in the Thai population [27]. A consistent association of the cases of carbamazepine-induced SJS/TEN were reported among the carriers of the *HLA-B**15:02 allele in this Thai population [20, 28]. Our findings justify the strongest association

of the *HLA-B**15:02 allele in the prediction of carbamazepine-induced SJS/TEN. In our study, we observed that the *HLA-B**15:02 allele was not specific for carbamazepine-induced SJS/TEN only, but it was also significantly associated with carbamazepine-induced MPE. However, a previous study by Hung et al. reported the phenotype-specific *HLA* association of carbamazepine-induced cADRs [3]. This discrepancy might be due to the different study populations. We observed the first evidence of a significant association of the *HLA-B**15:21 allele with carbamazepine-induced SJS/TEN in Thai subjects. *HLA-B**15:21 allele belongs to the *HLA-B*75 family, which consists of the *HLA-B**15:02 allele as well [29]. Jaruthamsophon et al. reported that *HLA-B**15:21 was associated with carbamazepine-induced SJS in different populations and that a patient without the *HLA-B**15:02 allele may be at a risk of carbamazepine-induced SJS due to the presence of the *HLA-B**15:21 allele, another *HLA-B*75 serotype marker [21]. We can conclude that the presence of alternative forms of *HLA* alleles belonging to the same subfamilies of serotypes might contribute to the susceptibility to cADRs. These observations imply that members of the *HLA-B*75 serotype encode proteins sharing a similar conformation for carbamazepine binding and presentation and trigger the immune response of SJS caused by carbamazepine [19].

In our study, we also found the association of the *HLA-B**58:01 allele with carbamazepine-induced MPE and DRESS. In contrast to our finding, Cheung et al. noted

TABLE 2: Association of *HLA-B* alleles with carbamazepine-induced cADRs.

<i>HLA-B</i> alleles	Carbamazepine-induced cADRs (<i>n</i> = 38)	Controls (<i>n</i> = 271)	Thai population (<i>n</i> = 470)	Carbamazepine-induced cADRs cases versus tolerant controls OR (95% CI)	<i>P</i> value	Carbamazepine-induced cADRs cases versus Thai population OR (95% CI)	<i>P</i> value
<i>B</i> * 07:05	3 (7.89%)	12 (4.43%)	24 (5.11%)	1.85 (0.50–6.88)	0.357	1.59 (0.46–5.55)	0.4649
<i>B</i> * 13:01	1 (2.63%)	37 (13.65%)	54 (11.49%)	0.17 (0.02–1.28)	0.063	0.21 (0.03–1.55)	0.106
<i>B</i> * 13:02	1 (2.63%)	6 (2.21%)	20 (4.26%)	1.19 (0.14–10.19)	1.000	0.61 (0.08–4.66)	1.000
<i>B</i> * 15:01	1 (2.63%)	10 (3.69%)	5 (1.06%)	0.71 (0.09–5.67)	1.000	2.51 (0.29–22.08)	0.374
<i>B</i> * 15:02	17 (44.74%)	11 (4.06%)	71 (15.11%)	19.13 (7.94–46.09)	7.35×10^{-12} *	4.55 (2.29–9.05)	3.44×10^{-6} *
<i>B</i> * 15:21	2 (5.26%)	4 (1.48%)	2 (0.43%)	3.71 (0.66–20.97)	0.161	13.00 (1.78–95.01)	0.030*
<i>B</i> * 18:01	4 (10.53%)	29 (10.70%)	36 (7.66%)	0.98 (0.33–2.97)	0.974	1.42 (0.48–3.22)	0.529
<i>B</i> * 18:15	2 (5.26%)	0 (0.00%)	0 (0.00%)	15.06 (1.33–170.25)	0.041*	26.11 (2.31–294.90)	0.016*
<i>B</i> * 27:04	2 (5.26%)	12 (4.43%)	19 (4.04%)	1.20 (0.26–5.58)	0.685	1.32 (0.30–5.89)	0.665
<i>B</i> * 27:06	1 (2.63%)	8 (2.95%)	12 (2.55%)	0.89 (0.11–7.31)	1.000	1.03 (0.13–8.15)	1.000
<i>B</i> * 40:01	5 (13.16%)	41 (15.13%)	58 (12.34%)	0.85 (0.31–2.31)	0.749	1.08 (0.40–2.87)	0.883
<i>B</i> * 44:03	3 (7.89%)	20 (7.38%)	42 (8.94%)	1.08 (0.30–3.81)	0.910	0.47 (0.14–1.59)	0.223
<i>B</i> * 46:01	8 (21.05%)	64 (23.62%)	122 (25.96%)	0.86 (0.38–1.98)	0.718	0.77 (0.34–1.72)	0.524
<i>B</i> * 51:01	5 (13.16%)	21 (7.75%)	40 (8.51%)	1.80 (0.64–5.11)	0.267	1.63 (0.60–4.41)	0.337
<i>B</i> * 56:04	1 (2.63%)	1 (0.37%)	12 (2.55%)	7.30 (0.45–119.17)	0.231	1.03 (0.13–8.15)	1.000
<i>B</i> * 57:01	1 (2.63%)	9 (3.32%)	11 (2.34%)	0.79 (0.10–6.39)	1.000	1.13 (0.14–8.98)	0.611
<i>B</i> * 58:01	8 (21.05%)	22 (8.12%)	57 (12.13%)	3.02 (1.24–7.38)	0.015*	1.93 (0.85–4.42)	0.119

cADRs: cutaneous adverse drug reactions; OR: odds ratio; 95% CI: confidence interval 95%. * *P* value less than 0.05.

TABLE 3: Association of *HLA-B* alleles with carbamazepine-induced MPE.

<i>HLA-B</i> alleles	Carbamazepine-induced MPE (<i>n</i> = 17)	Controls (<i>n</i> = 271)	Thai population (<i>n</i> = 470)	Carbamazepine-induced MPE cases versus tolerant controls OR (95% CI)	<i>P</i> value	Carbamazepine-induced MPE cases versus Thai population OR (95% CI)	<i>P</i> value
<i>B</i> * 07:05	1 (5.88%)	12 (4.43%)	24 (5.11%)	1.44 (0.18–11.81)	0.533	1.234 (0.16–9.78)	0.576
<i>B</i> * 13:02	1 (5.88%)	6 (2.21%)	20 (4.26%)	2.94 (0.33–26.05)	0.334	1.50 (0.19–11.93)	0.512
<i>B</i> * 15:02	4 (23.52%)	11 (4.06%)	71 (15.11%)	7.27 (2.04–25.97)	0.002*	2.30 (0.36–4.67)	0.721
<i>B</i> * 18:01	1 (5.88%)	29 (10.70%)	36 (7.66%)	0.19 (0.03–1.40)	0.098	0.80 (0.10–6.26)	1.000
<i>B</i> * 18:15	1 (5.88%)	0 (0.00%)	0 (0.00%)	18.07 (1.08–303.14)	0.108	31.33 (1.87–525.19)	0.065
<i>B</i> * 27:04	1 (5.88%)	12 (4.43%)	19 (4.04%)	1.44 (0.18–11.81)	0.533	1.58 (0.20–12.61)	0.495
<i>B</i> * 40:01	3 (17.65%)	41 (15.13%)	58 (12.34%)	1.30 (0.35–4.74)	0.720	1.64 (0.45–5.93)	0.438
<i>B</i> * 44:03	2 (11.77%)	20 (7.38%)	42 (8.94%)	1.72 (0.37–8.11)	0.369	1.46 (0.32–6.62)	0.648
<i>B</i> * 46:01	3 (17.65%)	64 (23.62%)	122 (25.96%)	0.69 (0.19–2.49)	0.574	0.66 (0.18–2.35)	0.772
<i>B</i> * 51:01	3 (17.65%)	21 (7.75%)	40 (8.51%)	2.55 (0.69–9.60)	0.166	2.30 (0.65–8.35)	0.204
<i>B</i> * 57:01	1 (5.88%)	9 (3.32%)	11 (2.34%)	1.94 (0.23–16.34)	0.442	2.78 (0.34–22.96)	0.334
<i>B</i> * 58:01	5 (29.41%)	22 (8.12%)	57 (12.13%)	4.74 (1.53–14.66)	0.007*	3.03 (1.03–8.88)	0.045*

MPE: maculopapular exanthema; OR: odds ratio; 95% CI: confidence interval 95%. * *P* value less than 0.05.

TABLE 4: Association of HLA-B alleles with carbamazepine-induced SJS/TEN.

HLA-B alleles	Carbamazepine-induced SJS/TEN (n = 16)	Controls (n = 271)	Thai population (n = 470)	Carbamazepine-induced SJS/TEN cases versus tolerant controls OR (95% CI)	P value	Carbamazepine-induced SJS/TEN cases versus Thai population OR (95% CI)	P value
B*07:05	2 (12.50%)	12 (4.43%)	24 (5.11%)	3.08 (0.63–12.13)	0.165	2.65 (0.57–12.35)	0.213
B*13:01	1 (6.25%)	37 (13.65%)	54 (11.49%)	0.40 (0.05–3.07)	0.709	0.48 (0.06–3.70)	0.707
B*15:01	1 (6.25%)	10 (3.69%)	5 (1.06%)	1.63 (0.20–13.55)	0.494	5.81 (0.64–52.67)	0.193
B*15:02	12 (75.00%)	11 (4.06%)	71 (15.11%)	70.91 (19.67–255.65)	4.46×10^{-13} *	18.26 (5.79–57.61)	6.9×10^{-8} *
B*15:21	2 (12.50%)	4 (1.48%)	2 (0.43%)	9.54 (1.61–56.57)	0.013*	19.14 (2.51–146.09)	0.004*
B*18:01	2 (12.50%)	29 (10.70%)	36 (7.66%)	1.19 (0.26–5.51)	0.822	1.72 (0.38–7.88)	0.483
B*18:15	1 (6.25%)	0 (0.00%)	0 (0.00%)	16.94 (1.01–183.39)	0.114	29.38 (1.76–490.97)	0.069
B*44:03	1 (6.25%)	20 (7.38%)	42 (8.94%)	0.78 (0.10–6.22)	1.000	0.37 (0.05–2.89)	0.484
B*46:01	4 (25.00%)	64 (23.62%)	122 (25.96%)	1.08 (0.34–3.46)	0.899	0.96 (0.30–3.03)	0.947
B*56:04	1 (6.25%)	1 (0.37%)	12 (2.55%)	16.88 (1.01–282.35)	0.115	2.39 (0.29–19.48)	0.374
B*58:01	1 (6.25%)	22 (8.12%)	57 (12.13%)	0.71 (0.09–5.59)	1.000	0.45 (0.06–3.48)	0.707

SJS/TEN: Stevens-Johnson syndrome/toxic epidermal necrolysis; OR: odds ratio; 95% CI: confidence interval 95%. * P value less than 0.05.

TABLE 5: Association of *HLA-B* alleles with carbamazepine-induced DRESS.

<i>HLA-B</i> alleles	Carbamazepine-induced DRESS (<i>n</i> = 5)	Controls (<i>n</i> = 271)	Thai population (<i>n</i> = 470)	Carbamazepine-induced DRESS cases versus tolerant controls OR (95% CI)	<i>P</i> value	Carbamazepine-induced DRESS cases versus Thai population OR (95% CI)	<i>P</i> value
<i>B</i> * 15:02	1 (20.00%)	11 (4.06%)	71 (15.11%)	5.91 (0.61–57.36)	0.126	1.41 (0.16–12.75)	0.562
<i>B</i> * 18:01	1 (20.00%)	29 (10.70%)	36 (7.66%)	2.09 (0.23–19.30)	0.440	3.01 (0.33–27.68)	0.325
<i>B</i> * 27:04	1 (20.00%)	12 (4.43%)	19 (4.04%)	5.40 (0.56–52.04)	0.216	5.93 (0.63–55.68)	0.194
<i>B</i> * 27:06	1 (20.00%)	8 (2.95%)	12 (2.55%)	8.22 (0.82–82.09)	0.154	9.54 (0.99–91.90)	0.130
<i>B</i> * 40:01	2 (40.00%)	41 (15.13%)	58 (12.34%)	3.74 (0.61–23.08)	0.174	4.74 (0.78–28.94)	0.122
<i>B</i> * 51:01	1 (20.00%)	21 (7.75%)	40 (8.51%)	2.98 (0.32–27.85)	0.339	2.69 (0.29–24.63)	0.382
<i>B</i> * 58:01	2 (40.00%)	22 (8.12%)	57 (12.13%)	7.55 (1.20–47.58)	0.032*	4.83 (0.79–29.53)	0.088

DRESS: drug reaction with eosinophilia and systemic symptoms; OR: odds ratio; 95% CI: confidence interval 95%. * *P* value less than 0.05.

FIGURE 1: The “pharmacological interaction with immune receptors (p-i)” model of immune activation during carbamazepine-induced hypersensitivity reactions.

in Han Chinese that the presence of the *HLA-B* 58:01* allele appears to be protective against the development of carbamazepine-induced SJS/TEN [30]. A meta-analysis investigating the association of *HLA-B* alleles and carbamazepine-induced SJS/TEN also found that the *HLA-B* 58:01* allele was a protective marker among Asian populations [31]. From these observations, we can conclude that genetic susceptibility to carbamazepine-induced cADRs is phenotype-specific. The *HLA-B* 58:01* allele is mainly associated with allopurinol-induced MPE, DRESS, and SJS/TEN in the Thai population [22, 32]. There are structural dissimilarities between carbamazepine and allopurinol; therefore, the details of the mechanism, including how exactly the *HLA-B* 58:01* allele interacts with each drug and exhibits the immune response, should be explored in future studies. Genetic screening of the *HLA-B* 15:02* allele in isolation will fail to prevent carbamazepine-induced MPE/DRESS. The association of the *HLA-B* 58:01* allele with carbamazepine-induced MPE and DRESS indicates the role of multiple *HLA-B* alleles, and the genetic testing of these alleles will improve the prevention of carbamazepine-induced cADRs. The *P* value for the association of the *HLA-B* 58:01* allele with carbamazepine-induced DRESS is just below the margin

of significance ($P = 0.032$). This finding must be considered preliminary and further studies are required to confirm this association of the *HLA-B* 58:01* allele with carbamazepine-induced DRESS.

The pathogenesis of these carbamazepine-induced hypersensitivity reactions needs further research, due to the role of genetic and host factors in carbamazepine-induced cADRs. The role of carbamazepine-specific T cells and its T cell receptors (TCRs) in the pathogenesis of carbamazepine-induced cADRs must be documented to evaluate the mechanism of carbamazepine-induced cADRs [33]. As illustrated in Figure 1, the “pharmacological interaction with immune receptors (p-i)” concept is a useful model to explain how carbamazepine triggers an immune-mediated hypersensitivity reactions [10].

Our study has provided substantial evidence of the development of MPE, SJS/TEN, and DRESS among carbamazepine-treated patients with *HLA* risk alleles. Screening of the risk alleles before carbamazepine use in the Thai population will significantly reduce cADRs with the exclusion of high-risk patients. We did not carry out an analysis of the involvement of *HLA-A* and *HLA-C* alleles in carbamazepine-induced hypersensitivity reactions, so this

might limit the scope of the application of our findings in clinical settings. Therefore, further studies should include association analysis of *HLA-A* and *HLA-C* variants with cADRs in Thai population. The adjusted significance level after Bonferroni's correction is 0.003 with 17 *HLA-B* alleles tested. Only the *HLA-B**15:02 allele remained significant with $P < 0.003$ after Bonferroni adjustment. Because, the smallest P value in Tables 2–5 is >0.003 , no other alleles are deemed significant after Bonferroni adjustment.

5. Conclusions

We found a strong association between the *HLA-B**15:02 allele and carbamazepine-induced SJS/TEN and MPE in Thai patients. We also reported an association of the *HLA-B**15:21 allele with carbamazepine-induced SJS/TEN providing a new perspective of the pharmacogenetic linkage. In addition, the *HLA-B**58:01 allele was also found to be a significant predictor of carbamazepine-induced MPE and DRESS in Thai patients. These findings may need to be confirmed before clinical interpretation and usage with the inclusion of larger sample sizes in further studies. Testing multiple related *HLA* alleles will aid in more reliable evaluation of the risks for developing SJS/TEN and MPE in patients prior to taking carbamazepine.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This study was supported by grants from the Faculty of Medicine Ramathibodi Hospital, Mahidol University, and THAI-SCAR project: WCU-002-HR-57, Chulalongkorn University. The authors thank the study participants and staff of the Pharmacogenomics and Personalized Medicine Laboratory, Ramathibodi Hospital.

References

- [1] P. T. Illing, A. W. Purcell, and J. McCluskey, "The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions," *Immunogenetics*, vol. 69, no. 8-9, pp. 617–630, 2017.
- [2] T. D. Fernandez, G. Canto, and M. Blanca, "Molecular mechanisms of maculopapular exanthema," *Current Opinion in Infectious Diseases*, vol. 22, no. 3, pp. 272–278, 2009.
- [3] S. I. Hung, W. H. Chung, S. H. Jee et al., "Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions," *Pharmacogenetics and Genomics*, vol. 16, no. 4, pp. 297–306, 2006.
- [4] T. Z. Vern-Gross and A. Kowal-Vern, "Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis syndrome in patients undergoing radiation therapy: a literature review," *American Journal of Clinical Oncology*, vol. 37, no. 5, pp. 506–513, 2014.
- [5] J. Thankachen and V. Agarwal, "Challenges in diagnosis, management, and treatment of allopurinol-induced DRESS syndrome: case report and literature review," *American Journal of Therapeutics*, vol. 22, no. 3, pp. e77–e83, 2015.
- [6] G. E. Besli, S. Yildirim, K. Yilmaz, and E. Yuksel, "DRESS syndrome or hematologic malignancy?: a case report of a 4-year-old boy," *Pediatric Emergency Care*, vol. 33, no. 7, pp. 494–496, 2017.
- [7] H. M. Corneli, "DRESS syndrome: drug reaction with eosinophilia and systemic symptoms," *Pediatric Emergency Care*, vol. 33, no. 7, pp. 499–502, 2017.
- [8] M. Shirzadi, A. Reimers, G. Helde, W. Sjursen, and E. Brodtkorb, "No association between non-bullous skin reactions from lamotrigine and heterozygosity of UGT1A4 genetic variants *2(P24T) or *3(L48V) in Norwegian patients," *Seizure*, vol. 45, pp. 169–171, 2017.
- [9] S. C. Su, S. I. Hung, W. L. Fan, R. L. Dao, and W. H. Chung, "Severe cutaneous adverse reactions: the pharmacogenomics from research to clinical implementation," *International Journal of Molecular Sciences*, vol. 17, no. 11, 2016.
- [10] W. H. Chung, C. W. Wang, and R. L. Dao, "Severe cutaneous adverse drug reactions," *The Journal of Dermatology*, vol. 43, no. 7, pp. 758–766, 2016.
- [11] L. Dean, "Carbamazepine Therapy and HLA Genotypes," in *Medical Genetics Summaries*, V. Pratt, H. McLeod, L. Dean, A. Malheiro and W. Rubinstein, Eds., pp. 87–97, National Center for Biotechnology Information (US), Bethesda, MD, USA, 2012.
- [12] W. H. Chung, S. I. Hung, H. S. Hong et al., "Medical genetics: a marker for Stevens–Johnson syndrome," *Nature*, vol. 428, no. 6982, p. 486, 2004.
- [13] S. G. Leckband, J. R. Kelsoe, H. M. Dunnenberger et al., "Clinical pharmacogenetics implementation consortium guidelines for *HLA-B* genotype and carbamazepine dosing," *Clinical Pharmacology and Therapeutics*, vol. 94, no. 3, pp. 324–328, 2013.
- [14] P. B. Ferrell Jr. and H. L. McLeod, "Carbamazepine, *HLA-B**1502 and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations," *Pharmacogenomics*, vol. 9, no. 10, pp. 1543–1546, 2008.
- [15] W. Tangamornsuksan, N. Chaiyakunapruk, R. Somkruea, M. Lohitnavy, and W. Tassaneeyakul, "Relationship between the *HLA-B**1502 allele and carbamazepine-induced Stevens–Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis," *JAMA Dermatology*, vol. 149, no. 9, pp. 1025–1032, 2013.
- [16] S. Grover and R. Kukreti, "HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis," *Pharmacogenetics and Genomics*, vol. 24, no. 2, pp. 94–112, 2014.
- [17] M. McCormack, A. Alfirevic, S. Bourgeois et al., "HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans," *The New England Journal of Medicine*, vol. 364, no. 12, pp. 1134–1143, 2011.
- [18] E. Genin, D. P. Chen, S. I. Hung et al., "HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis," *The Pharmacogenomics Journal*, vol. 14, no. 3, pp. 281–288, 2014.
- [19] Y. H. Hsiao, R. C. Y. Hui, T. Wu et al., "Genotype–phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations,"

- Journal of Dermatological Science*, vol. 73, no. 2, pp. 101–109, 2014.
- [20] W. Tassaneeyakul, S. Tiamkao, T. Jantararoungtong et al., “Association between *HLA-B*1502* and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population,” *Epilepsia*, vol. 51, no. 5, pp. 926–930, 2010.
- [21] K. Jaruthamsophon, V. Tipmanee, A. Sangiemchoey, C. Sukasem, and P. Limprasert, “*HLA-B*15:21* and carbamazepine-induced Stevens-Johnson syndrome: pooled-data and in silico analysis,” *Scientific Reports*, vol. 7, article 45553, 2017.
- [22] C. Sukasem, T. Jantararoungtong, P. Kuntawong et al., “*HLA-B*58:01* for allopurinol-induced cutaneous adverse drug reactions: implication for clinical interpretation in Thailand,” *Frontiers in Pharmacology*, vol. 7, p. 186, 2016.
- [23] Y. W. Shi, F. L. Min, D. Zhou et al., “*HLA-A*24:02* as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions,” *Neurology*, vol. 88, no. 23, pp. 2183–2191, 2017.
- [24] Y. C. Chen, Y. T. Cho, C. Y. Chang, and C. Y. Chu, “Drug reaction with eosinophilia and systemic symptoms: a drug-induced hypersensitivity syndrome with variable clinical features,” *Dermatologica Sinica*, vol. 31, no. 4, pp. 196–204, 2013.
- [25] N. Kaniwa and Y. Saito, “Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury,” *Journal of Human Genetics*, vol. 58, no. 6, pp. 317–326, 2013.
- [26] T. Ozeki, T. Mushiroda, A. Yowang et al., “Genome-wide association study identifies *HLA-A*3101* allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population,” *Human Molecular Genetics*, vol. 20, no. 5, pp. 1034–1041, 2011.
- [27] C. Lochareonkul, J. Loplumlert, C. Limotai et al., “Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with *HLA-B*1502* allele in Thai population,” *Epilepsia*, vol. 49, no. 12, pp. 2087–2091, 2008.
- [28] K. Kulkantrakorn, W. Tassaneeyakul, S. Tiamkao et al., “*HLA-B*1502* strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain,” *Pain Practice*, vol. 12, no. 3, pp. 202–208, 2012.
- [29] A. Puangpetch, N. Koomdee, M. Chamnanphol et al., “*HLA-B* allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity,” *Frontiers in Genetics*, vol. 5, p. 478, 2015.
- [30] Y. K. Cheung, S. H. Cheng, E. J. M. Chan, S. V. Lo, M. H. L. Ng, and P. Kwan, “*HLA-B* alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese,” *Epilepsia*, vol. 54, no. 7, pp. 1307–1314, 2013.
- [31] Q. Wang, S. Sun, M. Xie, K. Zhao, X. Li, and Z. Zhao, “Association between the *HLA-B* alleles and carbamazepine-induced SJS/TEN: a meta-analysis,” *Epilepsy Research*, vol. 135, pp. 19–28, 2017.
- [32] N. Saksit, W. Tassaneeyakul, N. Nakkam et al., “Risk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population,” *Pharmacogenetics and Genomics*, vol. 27, no. 7, pp. 255–263, 2017.
- [33] M. Pirmohamed, D. A. Ostrov, and B. K. Park, “New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity,” *The Journal of Allergy and Clinical Immunology*, vol. 136, no. 2, pp. 236–244, 2015.